DermSat-7量表在银屑病患者治疗满意度评估中的验证
本研究为多中心调查,纳入142例成年银屑病患者,评估皮肤病特异性治疗满意度量表DermSat-7的结构效度、内部一致性、建构效度和重测信度。结果显示DermSat-7具有单维性,效度和信度良好,可能适用于银屑病患者的治疗满意度测量。
要点
- DermSat-7在银屑病患者中表现出良好的结构效度和内部一致性。
- DermSat-7与TSQM-9相关性较强,支持其建构效度。
- 重测信度组内相关系数为0.85,提示稳定性高。
核心结论
- DermSat-7可能是测量银屑病患者治疗满意度的有效且可靠的工具。
研究设计与样本
- 多中心调查,2020年7月至2023年4月在美国三家皮肤科门诊纳入142例成年银屑病患者。
主要发现
- 探索性和验证性因子分析支持DermSat-7的单维性。
- 有效性和便利性领域的Cronbach α分别为0.88和0.81。
- DermSat-7与TSQM-9子分数相关性:有效性ρ=0.75,便利性ρ=0.66,总体满意度ρ=0.70,均P<.001。
- 组内相关系数为0.85,提示重测信度高。
关键数值与推荐
- 基于PASI/PGA评分的组间差异与预设假设一致。
临床怎么用
- DermSat-7可用于银屑病患者治疗满意度的临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A critical need exists for developing a validated dermatologic-specific treatment satisfaction instrument. OBJECTIVE: To evaluate the structural validity, internal consistency, construct validity, and test-retest reliability of the 7-item dermatology-specific treatment satisfaction (DermSat-7) instrument in patients with psoriasis. DESIGN, SETTING, AND PARTICIPANTS: This survey study was conducted from July 2020 to April 2023 in dermatology outpatient clinics at the University of Southern California, Brigham and Women's Hospital, and Mount Sinai Union Square and included adults (aged ≥18 years) with psoriasis who were fluent in English. On day 1, the clinician at the study sites assessed psoriasis disease severity in person using the Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Physician Global Assessment (PGA). On day 1, study participants completed the DermSat-7, the generic 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), and the Dermatology Life Quality Index (DLQI). They also answered demographic questions and reported their own disease severity using the Patient Global Assessment (PtGA). On day 14 (±2 days), the patient then completed the DermSat-7 and PtGA a second time. MAIN OUTCOMES AND MEASURES: The DermSat-7 is a 7-item self-administered instrument with a recall period of 14 days that assesses patient satisfaction with their treatments across various inflammatory dermatology diseases, including psoriasis. Construct validity, structural validity, internal consistency, and test-retest reliability of DermSat-7 were assessed as defined by the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) taxonomy and reported following the COSMIN reporting guideline for studies on measurement properties. RESULTS: The analysis included 142 patients with psoriasis (mean [SD] age, 51.1 [15.5] years; 77 males [54.2%]). Exploratory factor analysis and confirmatory factor analysis supported the unidimensionality of the DermSat-7 domains. The internal consistency of the effectiveness and convenience domains was high with a Cronbach α of 0.88 and 0.81, respectively. Regarding construct validity, differences between groups based on PASI/PGA scores were aligned with preexisting hypotheses, and the correlations between DermSat-7 and TSQM-9 subscores were strong to very strong (ρ = 0.75 for effectiveness; ρ = 0.66 for convenience; and ρ = 0.70 for overall satisfaction; all P < .001). Intraclass correlation was 0.85, indicating high test-retest reliability. CONCLUSIONS AND RELEVANCE: This survey study found that the DermSat-7 may be a valid and reliable instrument for measuring treatment satisfaction in patients with psoriasis.
引用
- Armstrong AW, Lee K, Yee D, et al. Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis. JAMA Dermatol. 2025. PMID: 40009402. doi:10.1001/jamadermatol.2024.6567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。